Arkin Bio

Arkin Bio is an Israeli life sciences venture capital firm that invests in early and mid-stage biotech companies.

Venture Capital Active Herzliya, Israel Est. 2016
Visit website ↗
Last updated 2026-07-20
Portfolio
3
in our dataset
Rounds participated
4
Rounds led
0
Rounds' value
$50.2M
total disclosed, rounds participated
Stages
Seed, A Round, Pre-Seed

About

Arkin Bio Ventures is a Tel Aviv-based life sciences venture capital firm founded in 2016 as part of Arkin Capital, a diversified global investment manager with over $2 billion in assets under management across twelve funds. Arkin Bio operates as a joint venture between Phoenix Group (49%) and Arkin Holdings (51%). The firm identifies, invests in, and accompanies innovative early and mid-stage companies with breakthroughs in areas such as immunotherapy, cancer, metabolism, microbiome, central nervous system, autoimmune diseases, orphan diseases, and drug-delivery platforms. Arkin Bio's management team leads and supports its portfolio companies through the hurdles of drug development, towards the proof-of-concept stage and beyond, to significant value creation. Arkin Bio currently manages a total of over $600 million for investments in the health sector.

Portfolio · 3

Metabomed
Target-inhibiting Anticancer Drugs
2 rounds $30.5M committed Latest: 2019-12
Pi Therapeutics
Inhibitors for Cancer Treatment
1 round $19.7M committed Latest: 2019-05
ARTSaVIT
Cancer Apoptosis Technology
1 round Latest: 2017-01

Investment activity

1 portfolio exit on record.

Portfolio by sector

Health Tech & Life Sciences7
Agriculture & Food Technologies1

Funds · 3

  • 3 — $100M Jan 2026
  • 2 — $140M Mar 2020
  • 1 — $60M Jun 2016

Q&A

What is Arkin Bio's primary investment focus?
Arkin Bio primarily focuses on early and mid-stage companies with breakthroughs in areas such as immunotherapy, cancer, metabolism, microbiome, central nervous system, autoimmune diseases, orphan diseases, and drug-delivery platforms. Their portfolio shows a strong concentration in Health Tech & Life Sciences.
Which notable exit has Arkin Bio had recently?
Arkin Bio had a notable exit in October 2023 when portfolio company BioSight was acquired by Ayala Pharmaceuticals.
What is the most recent fund raised by Arkin Bio?
Arkin Bio raised Fund 3, amounting to $100 million, in January 2026.
Can you name some of Arkin Bio's portfolio companies?
Arkin Bio's portfolio includes companies such as Kamari Pharma, which focuses on small molecule inhibitors.
What is Arkin Bio's investment stage preference?
Arkin Bio invests in Seed, A Round, and Pre-Seed stages.
Who are the key individuals leading Arkin Bio?
Dr. Pini Orbach serves as a Managing Partner at Arkin Bio, and Dr. Alon Lazarus is a Biotech Investment Manager.
What is the structure of Arkin Bio Ventures?
Arkin Bio Ventures is a joint venture between Arkin Holdings (51%) and Phoenix Group (49%).
How much capital did Arkin Bio raise for its second fund?
Arkin Bio raised $140 million for Fund 2 in March 2020.
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)